Glucagon-like peptides: Regulators of cell proliferation, differentiation, and apoptosis

Molecular Endocrinology

Volumn 17, Issue 2, 2003, Pages 161-171

  Drucker, Daniel J ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; BROXURIDINE; CASPASE; CYCLOHEXIMIDE; EXENDIN 4; FLUOROURACIL; G PROTEIN COUPLED RECEPTOR; GLUCAGON; GLUCAGON LIKE PEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 AGONIST; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCAGON LIKE PEPTIDE 2; GLUCAGON LIKE PEPTIDE 2 AGONIST; GLUCAGON RECEPTOR; GLUCOSE; HORMONE DERIVATIVE; IBOTENIC ACID; INDOMETACIN; IRINOTECAN; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; NEUROPEPTIDE; NIFEDIPINE; NN 221; NONSTEROID ANTIINFLAMMATORY AGENT; PD 98054; PEPTIDE HORMONE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE INHIBITOR; STREPTOZOCIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; CELL DIFFERENTIATION; CELL LINE; CELL PROLIFERATION; CELL PROTECTION; CELL SURVIVAL; CELL TYPE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENDOCRINE CELL; ENERGY ABSORPTION; ENERGY METABOLISM; ENTEROPATHY; EXOCRINE CELL; FETUS; FOOD INTAKE; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL MUCOSA; GENETIC TRANSCRIPTION; HOMEOSTASIS; HORMONE ACTION; HORMONE RELEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INSULIN RELEASE; INTESTINE; INTESTINE EPITHELIUM; INTESTINE INJURY; MOUSE; NERVE CELL; NEUROENDOCRINE SYSTEM; NEWBORN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PHENOTYPE; PRECURSOR; PRESERVATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; RAT; SHORT SURVEY; SIGNAL TRANSDUCTION; TISSUE REGENERATION; TREATMENT INDICATION;

ANIMALS; APOPTOSIS; CELL DIFFERENTIATION; CELL DIVISION; EXOCRINE GLANDS; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE 2; HUMANS; INTESTINES; ISLETS OF LANGERHANS; PEPTIDE FRAGMENTS; PEPTIDE HORMONES; PEPTIDES; PROTEIN PRECURSORS; RECEPTORS, GLUCAGON; SIGNAL TRANSDUCTION;

ANIMALIA;

EID: 0037312818     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2002-0306     Document Type: Short Survey

References (117)

1. Bell GI, Santerre RF, Mullenbach GT 1983 Hamster preproglucagon contains the sequence of glucagon and two related peptides. Nature 302:716-718
2. Heinrich G, Gros P, Lund PK, Bentley RC, Habener JF 1984 Pre-proglucagon messenger ribonucleic acid: nucleotide and encoded amino acid sequences of the rat pancreatic complementary deoxyribonucleic acid. Endocrinology 115:2176-2181
3. Mojsov S, Heinrich G, Wilson IB, Ravazzola M, Orci L, Habener JF 1986 Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing. J Biol Chem 261:11880-11889
4. Orskov C, Holst JJ, Poulsen SS, Kirkegaard P 1987 Pancreatic and intestinal processing of proglucagon in man. Diabetologia 30:874-881
5. Larsen PJ, Tang-Christensen M, Holst JJ, Orskov C 1997 Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem. Neuroscience 77:257-270
6. Lui EY, Asa SL, Drucker DJ, Lee YC, Brubaker PL 1990 Glucagon and related peptides in fetal rat hypothalamus in vivo and in vitro. Endocrinology 126:110-117
7. Lund PK, Goodman RH, Dee PC, Habener JF 1982 Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem. Proc Natl Acad Sci USA 79:345-349
8. Irwin DM 2001 Molecular evolution of proglucagon. Regul Pept 98:1-12
9. Drucker DJ, Philippe J, Mojsov S, Chick WL, Habener JF 1987 Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci USA 84:3434-3438
10. Kreymann B, Ghatei MA, Williams G, Bloom SR 1987 Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 2:1300-1304
11. Orskov C, Holst J J, Nielsen OV 1988 Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology 123:2009-2013
12. Mojsov S, Weir GC, Habener JF 1987 Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest 79:616-619
13. Drucker DJ 2001 Glucagon-like peptide 2. J Clin Endocrinol Metab 86:1759-1764
14. D'Alessio DA, Fujimoto WY, Ensinck JW 1989 Effects of glucagonlike peptide I(7-36) on release of insulin, glucagon, and somatostatin by rat pancreatic islet cell monolayer cultures. Diabetes 38:1534-1538
15. Komatsu R, Matsuyama T, Namba M, Watanabe N, Itoh H, Kono N, Tarui S 1989 Glucagonostatic and insulinotropic action of glucagonlike peptide I-(7-36)-amide. Diabetes 38:902-905
16. Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Nauck MA 1996 Gastric emptying, glucose responses, and insulin secretion aftera liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36)amide in type 2 (non-insulin dependent) diabetic patients. J Clin Endocrinol Metab 81:327-332
17. Schjoldager BTG, Mortensen PE, Christiansen J, Orskov C, Holst JJ 1989 GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in humans. Dig Dis Sci 34:703-708
18. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CMB, Meeran K, Choi SJ, Taylor GM, Heath MM, Lambert PD, Wilding JPH, Smith DM, Ghatei MA, Herbert J, Bloom SR 1996 A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379:69-72
19. Flint A, Raben A, Astrup A, Holst JJ 1998 Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 101:515-520
20. Drucker DJ 2001 Development of glucagon-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetes. Curr Pharm Des 7:1399-412
21. Drucker DJ 2001 Minireview: the glucagon-like peptides. Endocrinology 142:521-527
22. Thorens B 1992 Expression cloning of the pancreatic β cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc Natl Acad Sci USA 89:8641-8645
23. Skoglund G, Hussain MA, Holz GG 2000 Glucagon-like peptide 1 stimulates insulin gene promoter activity by protein kinase A-independent activation of the rat insulin I gene cAMP response element. Diabetes 49:1156-1164
24. Kashima Y, Miki T, Shibasaki T, Ozaki N, Miyazaki M, Yano H, Seino S 2001 Critical role of cAMP-GEFII/Rim2 complex in incretin-potentiated insulin secretion. J Biol Chem 276:46046-46053
25. 2+ release in INS-1 pancreatic β-cells. J Physiol 536:375-385
26. Zhou J, Wang X, Pineyro MA, Egan JM 1999 Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells. Diabetes 48:2358-2366
27. Hui H, Wright C, Perfetti R 2001 Glucagon-like peptide 1 induces differentiation of islet duodenal homeobox-1-positive pancreatic ductal cells into insulin-secreting cells. Diabetes 50:785-796
28. Zhou J, Pineyro MA, Wang X, Doyle ME, Egan JM 2002 Exendin-4 differentiation of a human pancreatic duct cell line into endocrine cells: involvement of PDX-1 and HNF3β transcription factors. J Cell Physiol 192:304-314
29. de la Tour D, Halvorsen T, Demeterco C, Tyrberg B, Itkin-Ansari P, Loy M, Yoo SJ, Hao E, Bossie S, Levine F 2001 β-Cell differentiation from a human pancreatic cell line in vitro and in vivo. Mol Endocrinol 15:476-483
30. Hardikar AA, Wang XY, Williams LJ, Kwok J, Wong R, Yao M, Tuch BE 2002 Functional maturation of fetal porcine β-cells by glucagon-like peptide 1 and cholecystokinin. Endocrinology 143:3505-3514
31. Movassat J, Beattie GM, Lopez AD, Hayek A 2002 Exendin 4 up-regulates expression of PDX 1 and hastens differentiation and maturation of human fetal pancreatic cells. J Clin Endocrinol Metab 87:4775-4781
32. Zulewski H, Abraham EJ, Gerlach MJ, Daniel PB, Moritz W, Muller B, Vallejo M, Thomas MK, Habener JF 2001 Multipotential nestin-positive stem cells isolated from adult pancreatic islets differentiate ex vivo into pancreatic endocrine, exocrine, and hepatic phenotypes. Diabetes 50:521-533
33. Abraham EJ, Leech CA, Lin JC, Zulewski H, Habener JF 2002 Insulinotropic hormone glucagon-like peptide-1 differentiation of human pancreatic islet-derived progenitor cells into insulin-producing cells. Endocrinology 143:3152-3161
34. Susini S, Roche E, Prentki M, Schlegel W 1998 Glucose and glucoincretin peptides synergize to induce c-fos, c-jun, junB, zif-268, and nur-77 gene expression in pancreatic β(INS-1) cells. FASEB J 12:1173-1182
35. Buteau J, Roduit R, Susini S, Prentki M 1999 Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in β (INS-1)-cells. Diabetologia 42:856-864
36. Wang X, Cahill CM, Pineyro MA, Zhou J, Doyle ME, Egan JM 1999 Glucagon-like peptide-1 regulates the β cell transcription factor, PDX-1, in insulinoma cells. Endocrinology 140:4904-4907
37. Buteau J, Foisy S, Rhodes CJ, Carpenter L, Biden TJ, Prentki M 2001 Protein kinase Cζ activation mediates glucagon-like peptide-1-induced pancreatic β-cell proliferation. Diabetes 50:2237-2243
38. 2+ influx through L-type voltage gated calcium channels mediate Raf-independent activation of extracellular regulated kinase in response to glucagon like peptide-1 in pancreatic β-cells. J Biol Chem 277:48146-48151 (first published 2 October 2002; 10.1074/jbc.M209165200)
39. Edvell A, Lindstrom P 1999 Initiation of increased pancreatic islet growth in young normoglycemic mice (Umeå +/?). Endocrinology 140:778-783
40. Xu G, Stoffers DA, Habener JF, Bonner-Weir S 1999 Exendin-4 stimulates both β-cell replication and neogenesis, resulting in increased β-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48:2270-2276
41. Perfetti R, Zhou J, Doyle ME, Egan JM 2000 Glucagon-like peptide-1 induces cell proliferation and pancreaticduodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology 141:4600-4605
42. Tourrel C, Bailbe D, Lacorne M, Meile MJ, Kergoat M, Portha B 2002 Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the β-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. Diabetes 51:1443-1452
43. Tourrel C, Bailbe D, Meile M-J, Kergoat M, Portha B 2001 Glucagon-like peptide-1 and exendin-4 stimulate β-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes 50:1562-1570
44. Stoffers DA, Kieffer TJ, Hussain MA, Drucker DJ, Egan JM, Bonner-Weir S, Habener JF 2000 Insulinotropic glucagon-like peptide-1 agonists stimulate expression of homeodomain protein IDX-1 and increase β-cell mass in mouse pancreas. Diabetes 49:741-748
45. Rolin B, Larsen MO, Gotfredsen CF, Deacon CF, Carr RD, Wilken M, Knudsen LB 2002 The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases β-cell mass in diabetic mice. Am J Physiol 283: E745-E752
46. Ling Z, Wu D, Zambre Y, Flamez D, Drucker DJ, Pipeleers DG, Schuit FC 2001 Glucagon-like peptide 1 receptor signaling influences topography of islet cells in mice. Virchows Arch 438:382-387
47. Scrocchi LA, Hill ME, Saleh J, Perkins B, Drucker DJ 2000 Elimination of GLP-1R signaling does not modify weight gain and islet adaptation in mice with combined disruption of leptin and GLP-1 action. Diabetes 49:1552-1560
48. De Leon DD, Deng S, Madani R, Ahima RS, Drucker DJ, Stoffers DA, Role of endogenous glucagon-like peptide-1 in islet regeneration following partial pancreatectomy. Diabetes, in press
49. Chen YE, Drucker DJ 1997 Tissue-specific expression of unique mRNAs that encode proglucagon-derived peptides or exendin 4 in the lizard. J Biol Chem 272:4108-4115
50. Drucker DJ, Ehrlich P, Asa SL, Brubaker PL 1996 Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci USA 93:7911-7916
51. Tsai C-H, Hill M, Drucker DJ 1997 Biological determinants of intestinotrophic properties of GLP-2 in vivo. Am J Physiol 272:G662-G668
52. Tsai C-H, Hill M, Asa SL, Brubaker PL, Drucker DJ 1997 Intestinal growth-promoting properties of glucagon-like peptide 2 in mice. Am J Physiol 273:E77-E84
53. Benjamin MA, McKay DM, Yang PC, Cameron H, Perdue MH 2000 Glucagon-like peptide-2 enhances intestinal epithelial barrier function of both transcellular and paracellular pathways in the mouse. Gut 47:112-119
54. Drucker DJ, Shi Q, Crivici A, Sumner-Smith M, Tavares W, Hill M, DeForest L, Cooper S, Brubaker PL 1997 Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV. Nat Biotechnol 15:673-677
55. Burrin DG, Stoll B, Jiang R, Petersen Y, Elnif J, Buddington RK, Schmidt M, Holst JJ, Hartmann B, Sangild PT 2000 GLP-2 stimulates intestinal growth in premature TPN-fed pigs by suppressing proteolysis and apoptosis. Am J Physiol 279:G1249-G1256
56. Jeppesen PB, Hartmann B, Thulesen J, Graff J, Lohmann J, Hansen BS, Tofteng F, Poulsen SS, Madsen JL, Holst JJ, Mortensen PB 2001 Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology 120:806-815
57. Ghatei MA, Goodlad RA, Taheri S, Mandir N, Brynes AE, Jordinson M, Bloom SR 2001 Proglucagon-derived peptides in intestinal epithelial proliferation: glucagon-like peptide-2 is a major mediator of intestinal epithelial proliferation in rats. Dig Dis Sci 46:1255-1263
58. Drucker DJ, DeForest L, Brubaker PL 1997 Intestinal response to growth factors administered alone or in combination with human [Gly2]glucagon-like peptide 2. Am J Physiol 273:G1252-G1262
59. Boushey RP, Yusta B, Drucker DJ 1999 Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis. Am J Physiol 277:E937-E947
60. Alavi K, Schwartz MZ, Palazzo JP, Prasad R 2000 Treatment of inflammatory bowel disease in a rodent model with the intestinal growth factor glucagon-like peptide-2. J Pediatr Surg 35:847-851
61. Kato Y, Yu D, Schwartz MZ 1999 Glucagon-like peptide-2 enhances small intestinal absorptive function and mucosal mass in vivo. J Pediatr Surg 34:18-20
62. Prasad R, Alavi K, Schwartz MZ 2000 Glucagon-like peptide-2 analogue enhances intestinal mucosal mass after ischemia and reperfusion. J Pediatr Surg 35:357-359
63. Prasad R, Alavi K, Schwartz MZ 2001 GLP-2α accelerates recovery of mucosal absorptive function after intestinal ischemia/reperfusion. J Pediatr Surg 36:570-572
64. Drucker DJ, Yusta B, Boushey RP, Deforest L, Brubaker PL 1999 Human [Gly2]-GLP-2 reduces the severity of colonic injury in a murine model of experimental colitis. Am J Physiol 276:G79-G91
65. Scott RB, Kirk D, MacNaughton WK, Meddings JB 1998 GLP-2 augments the adaptive response to massive intestinal resection in rat. Am J Physiol 275:G911-G921
66. Sigalet DL, Martin GR 2000 Hormonal therapy for short bowel syndrome. J Pediatr Surg 35:360-363; discussion 364
67. Fischer KD, Dhanvantari S, Drucker DJ, Brubaker PL 1997 Intestinal growth is associated with elevated levels of glucagon-like peptide-2 in diabetic rats. Am J Physiol 273:E815-E820
68. Hartmann B, Thulesen J, Hare KJ, Kissow H, Orskov C, Poulsen SS, Holst JJ 2002 Immunoneutralization of endogenous glucagon-like peptide-2 reduces adaptive intestinal growth in diabetic rats. Regul Pept 105:173-179
69. Chance WT, Foley-Nelson T, Thomas I, Balasubramaniam A 1997 Prevention of parenteral nutrition-induced gut hypoplasia by coinfusion of glucagon-like peptide-2. Am J Physiol 273:G559-G563
70. Chance WT, Sheriff S, Foley-Nelson T, Thomas I, Balasubramaniam A 2000 Maintaining gut integrity during parenteral nutrition of tumor-bearing rats: effects of glucagon-like peptide 2. Nutr Cancer 37:215-222
71. Munroe DG, Gupta AK, Kooshesh F, Vyas TB, Rizkalla G, Wang H, Demchyshyn L, Yang ZJ, Kamboj RK, Chen H, McCallum K, Sumner-Smith M, Drucker DJ, Crivici A 1999 Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2. Proc Natl Acad Sci USA 96:1569-1573
72. Yusta B, Somwar R, Wang F, Munroe D, Grinstein S, Klip A, Drucker DJ 1999 Identification of glucagon-like peptide-2 (GLP-2)-activated signaling pathways in baby hamster kidney fibroblasts expressing the rat GLP-2 receptor. J Biol Chem 274:30459-30467
73. Yusta B, Huang L, Munroe D, Wolff G, Fantaske R, Sharma S, Demchyshyn L, Asa SL, Drucker DJ 2000 Enteroendocrine localization of GLP-2 receptor expression. Gastroenterology 119:744-755
74. Bjerknes M, Cheng H 2001 Modulation of specific intestinal epithelial progenitors by enteric neurons. Proc Natl Acad Sci USA 98:12497-12502
75. Drucker DJ 2002 Gut adaptation and the glucagon-like peptides. Gut 50:428-435
76. Bregenholt S, Moldrup A, Knudsen LB, Petersen JS, The GLP-1 derivative NN2211 inhibits cytokine-induced apoptosis in primary rat β cells. Proc 61st Annual Meeting of the American Diabetes Association, Philadelphia, 2001, A31 (Abstract 125-OR)
77. Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ (29 October 2002) Glucagon-like peptide-1 receptor signaling modulates β cell apoptosis. J Biol Chem 10.1074/jbc. M209423200
78. Farilla L, Hui H, Bertolotto C, Kang E, Bulotta A, Di Mario U, Perfetti R 2002 Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 143:4397-4408
79. Wang Q, Brubaker PL 2002 Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice. Diabetologia 45:1263-1273
80. Perry T, Haughey NJ, Mattson MP, Egan JM, Greig NH 2002 Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J Pharmacol Exp Ther 302:881-888
81. Boushey RP, Yusta B, Drucker DJ 2001 Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor. Cancer Res 61:687-693
82. Yusta B, Boushey RP, Drucker DJ 2000 The glucagon-like peptide-2 receptor mediates direct inhibition of cellular apoptosis via a cAMP-dependent protein kinase-independent pathway. J Biol Chem 275:35345-35352
83. Yusta B, Estall J, Drucker DJ 2002 GLP-2 receptor activation engages Bad and glycogen synthase kinase 3 in a protein kinase A-dependent manner and prevents apoptosis following inhibition of phosphatidylinositol 3-kinase. J Biol Chem 277:24896-24906
84. Chang JY, Korolev W 1997 Cyclic AMP and sympathetic neuronal programmed cell death. Neurochem Int 31:161-167
85. Trumper A, Trumper K, Horsch D 2002 Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in β(INS-1)-cells. J Endocrinol 174:233-246
86. Villalba M, Bockaert J, Journot L 1997 Pituitary adenylate cyclase-activating polypeptide (PACAP-38) protects cerebellar granule neurons from apoptosis by activating the mitogen-activated protein kinase (MAP kinase) pathway. J Neurosci 17:83-90
87. Flaws JA, DeSanti A, Tilly KI, Javid RO, Kugu K, Johnson AL, Hirshfield AN, Tilly JL 1995 Vasoactive intestinal peptide-mediated suppression of apoptosis in the ovary: potential mechanisms of action and evidence of a conserved antiatretogenic role through evolution. Endocrinology 136:4351-4359
88. Delgado M, Garrido E, Martinez C, Leceta J, Gomariz RP 1996 Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptides (PACAP27) and PACAP38) protect CD4+CD8+ thymocytes from glucocorticoid-induced apoptosis. Blood 87:5152-5161
89. Delgado M, Ganea D 2001 Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit expression of Fas ligand in activated T lymphocytes by regulating c-Myc, NF-κB, NF-AT, and early growth factors 2/3. J Immunol 166:1028-1040
90. Lezoualc'h F, Engert S, Berning B, Behl C 2000 Corticotropin-releasing hormone-mediated neuroprotection against oxidative stress is associated with the increased release of non-amyloidogenic amyloid β precursor protein and with the suppression of nuclear factor-κB. Mol Endocrinol 14:147-159
91. Chun SY, Eisenhauer KM, Minami S, Billig H, Perlas E, Hsueh AJ 1996 Hormonal regulation of apoptosis in early antral follicles: follicle-stimulating hormone as a major survival factor. Endocrinology 137:1447-1456
92. Oehler MK, Norbury C, Hague S, Rees MC, Bicknell R 2001 Adrenomedullin inhibits hypoxic cell death by upregulation of Bcl-2 in endometrial cancer cells: a possible promotion mechanism for tumour growth. Oncogene 20:2937-2945
93. Todisco A, Ramamoorthy S, Witham T, Pausawasdi N, Srinivasan S, Dickinson CJ, Askari FK, Krametter D 2001 Molecular mechanisms for the antiapoptotic action of gastrin. Am J Physiol 280:G298-G307
94. Sato H, Abe Y, Noguchi M, Kurokawa K, Sakai H 1999 Inhibitory effect of thyrotropic hormone on apoptosis induced by actinomycin D in a functioning rat thyroid cell line. Endocr J 46:309-315
95. DeFea KA, Vaughn ZD, O'Bryan EM, Nishijima D, Dery O, Bunnett NW 2000 The proliferative and antiapoptotic effects of substance P are facilitated by formation of a β-arrestin-dependent scaffolding complex. Proc Natl Acad Sci USA 97:11086-11091
96. Leri A, Claudio PP, Li Q, Wang X, Reiss K, Wang S, Malhotra A, Kajstura J, Anversa P 1998 Stretch-mediated release of angiotensin II induces myocyte apoptosis by activating p53 that enhances the local reninangiotensin system and decreases the Bcl-2-to-Bax protein ratio in the cell. J Clin Invest 101:1326-1342
97. Goswami R, Dawson SA, Dawson G 1998 Cyclic AMP protects against staurosporine and wortmannin-induced apoptosis and opioid-enhanced apoptosis in both embryonic and immortalized (F-11κ7) neurons. J Neurochem 70:1376-1382
98. Sakuta H, Inaba K, Muramatsu S 1996 Calcitonin gene-related peptide enhances apoptosis of thymocytes. J Neuroimmunol 67:103-109
99. Suenobu N, Shichiri M, Iwashina M, Marumo F, Hirata Y 1999 Natriuretic peptides and nitric oxide induce endothelial apoptosis via a cGMP-dependent mechanism. Arterioscler Thromb Vasc Biol 19:140-146
100. Turner PR, Mefford S, Christakos S, Nissenson RA 2000 Apoptosis mediated by activation of the G protein-coupled receptor for parathyroid hormone (PTH)/PTH-related protein (PTHrP). Mol Endocrinol 14:241-254
101. Sharma K, Srikant CB 1998 G protein coupled receptor signaled apoptosis is associated with activation of a cation insensitive acidic endonuclease and intracellular acidification. Biochem Biophys Res Commun 242:134-140
102. Adams JW, Brown JH 2001 G-proteins in growth and apoptosis: lessons from the heart. Oncogene 20:1626-1634
103. Singh K, Communal C, Sawyer DB, Colucci WS 2000 Adrenergic regulation of myocardial apoptosis. Cardiovasc Res 45:713-719
104. Filippatos GS, Gangopadhyay N, Lalude O, Parameswaran N, Said SI, Spielman W, Uhal BD 2001 Regulation of apoptosis by vasoactive peptides. Am J Physiol 281: L749-L761
105. Turner RC, Cull CA, Frighi V, Holman RR 1999 Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 281:2005-2012
106. Gukovskaya AS, Gukovsky I, Jung Y, Mouria M, Pandol SJ 2002 Cholecystokinin induces caspase activation and mitochondrial dysfunction in pancreatic acinar cells. Roles in cell injury processes of pancreatitis. J Biol Chem 277:22595-22604
107. Trulsson LM, Svanvik J, Permert J, Gasslander T 2001 Cholecystokinin octapeptide induces both proliferation and apoptosis in the rat pancreas. Regul Pept 98:41-48
108. Pedersen WA, McCullers D, Culmsee C, Haughey NJ, Herman JP, Mattson MP 2001 Corticotropin-releasing hormone protects neurons against insults relevant to the pathogenesis of Alzheimer's disease. Neurobiol Dis 8:492-503
109. 2+-dependent protein kinase C-α. J Hepatol 34:284-291
110. Somai S, Gompel A, Rostene W, Forgez P 2002 Neurotensin counteracts apoptosis in breast cancer cells. Biochem Biophys Res Commun 295:482-488
111. Amling M, Neff L, Tanaka S, Inoue D, Kuida K, Weir E, Philbrick WM, Broadus AE, Baron R 1997 Bcl-2 lies downstream of parathyroid hormone-related peptide in a signaling pathway that regulates chondrocyte maturation during skeletal development. J Cell Biol 136:205-213
112. Chen HL, Demiralp B, Schneider A, Koh AJ, Silve C, Wang CY, McCauley LK 2002 Parathyroid hormone and parathyroid hormone-related protein exert both pro- and anti-apoptotic effects in mesenchymal cells. J Biol Chem 277:19374-19381
113. Cavallaro S, Copani A, D'Agata V, Musco S, Petralia S, Ventra C, Stivala F, Travali S, Canonico PL 1996 Pituitary adenylate cyclase activating polypeptide prevents apoptosis in cultured cerebellar granule neurons. Mol Pharmacol 50:60-66
114. Campard PK, Crochemore C, Rene F, Monnier D, Koch B, Loeffler JP 1997 PACAP type I receptor activation promotes cerebellar neuron survival through the cAMP/PKA signaling pathway. DNA Cell Biol 16:323-333
115. Szende B, Zalatnai A, Schally AV 1989 Programmed cell death (apoptosis) in pancreatic cancers of hamsters after treatment with analogs of both luteinizing hormone-releasing hormone and somatostatin. Proc Natl Acad Sci USA 86:1643-1647
116. Sharma K, Patel YC, Srikant CB 1996 Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3. Mol Endocrinol 10:1688-1696
117. Said SI, Dickman KG 2000 Pathways of inflammation and cell death in the lung: modulation by vasoactive intestinal peptide. Regul Pept 93:21-29